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CLINICAL AND POPULATION STUDIES
Carotid Intima-Media Thickness
Novel Loci, Sex-Specific Effects, and Genetic Correlations With Obesity and  
Glucometabolic Traits in UK Biobank
Rona J. Strawbridge, Joey Ward, Mark E.S. Bailey, Breda Cullen, Amy Ferguson, Nicholas Graham, Keira J.A. Johnston,  
Laura M. Lyall, Robert Pearsall, Jill Pell, Richard J. Shaw, Rachana Tank, Donald M. Lyall, Daniel J. Smith
OBJECTIVE: Atherosclerosis is the underlying cause of most cardiovascular disease, but mechanisms underlying atherosclerosis 
are incompletely understood. Ultrasound measurement of the carotid intima-media thickness (cIMT) can be used to measure 
vascular remodeling, which is indicative of atherosclerosis. Genome-wide association studies have identified many genetic 
loci associated with cIMT, but heterogeneity of measurements collected by many small cohorts have been a major limitation 
in these efforts. Here, we conducted genome-wide association analyses in UKB (UK Biobank; N=22 179), the largest single 
study with consistent cIMT measurements.
APPROACH AND RESULTS: We used BOLT-LMM software to run linear regression of cIMT in UKB, adjusted for age, sex, and 
genotyping chip. In white British participants, we identified 5 novel loci associated with cIMT and replicated most previously 
reported loci. In the first sex-specific analyses of cIMT, we identified a locus on chromosome 5, associated with cIMT in 
women only and highlight VCAN as a good candidate gene at this locus. Genetic correlations with body mass index and 
glucometabolic traits were also observed. Two loci influenced risk of ischemic heart disease.
CONCLUSIONS: These findings replicate previously reported associations, highlight novel biology, and provide new directions for 
investigating the sex differences observed in cardiovascular disease presentation and progression.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: atherosclerosis ◼ carotid artery ◼ coronary artery disease ◼ diabetes, type 2 ◼ genetics, association studies  
◼ intima-media thickness ◼ obesity
Atherosclerosis is the underlying cause of the majority of cardiovascular events and is characterized by vas-cular remodeling, incorporation of lipids into the vessel 
wall, and subsequent inflammation.1,2 Atherosclerosis is a 
systemic process that precedes clinical presentation of car-
diovascular events, such as stroke, by decades. Indeed, evi-
dence of vascular remodeling indicative of atherosclerosis 
has been observed as early as in adolescent age groups.3
See accompanying editorial on page 297
Atherosclerosis can be noninvasively assessed by 
ultrasound measurement of the carotid artery vessel wall, 
specifically the intima-media thickness (carotid intima-
media thickness [cIMT]). In some cases, cIMT assessment 
is used for monitoring after cardiovascular events, such as 
stoke, but could also be useful for screening individuals at 
high risk of cardiovascular events. Currently, use is limited 
as it requires specialist equipment and training, and high-
quality data analysis is laborious. Measurement of cIMT 
has been performed for research purposes, predomi-
nantly in cohorts recruited for the study of cardiovascular 
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disease. Although undeniably useful, the use of clinical 
cohorts does not cover the whole spectrum of atheroscle-
rotic burden in the population.
Genetic analyses of clinical cohorts have begun to iden-
tify single nucleotide polymorphisms (SNPs) associated with 
increased cIMT,4–7 which paves the way for better under-
standing of processes leading to cardiovascular events. A 
limitation for these studies (N=68 000) has been hetero-
geneity in recruitment and ultrasound methodology, which 
could lead to failure to detect some true genetic effects. In 
this respect, UKB (UK Biobank) provides an unprecedented 
opportunity to analyze IMT measurements in a very large 
cohort (N=22 000) with consistent recruitment and stan-
dardized cIMT measurements, analysis, and quality control.
We, therefore, set out primarily to identify genetic variants 
associated with cIMT in a large general population cohort. A 
secondary aim was to investigate the possibility of sex-spe-
cific genetic effects on IMT. Here, we demonstrate replica-
tion of previously reported associations, genetic correlations 
with cardiometabolic traits, novel biology and provide new 
directions for investigating the sex differences observed in 
cardiovascular disease presentation and progression.
METHODS
The individual-level data that underlie the findings of this study 
are available from UKB. Summary statistics resulting from this 
study are available from the corresponding author upon request.
Study Population
The UKB study has been described in detail previously.8,9 In 
brief, UKB recruited ≈500 000 participants from the United 
Kingdom between 2006 and 2010. Participants attended 1 of 
the 22 recruitment centers across the United Kingdom where 
they provided a blood sample for DNA extraction and biomarker 
analysis and completed questionnaires covering a wide range of 
medical, social and lifestyle information. All participants provided 
informed consent, and the study was conducted in accordance 
with the Helsinki Declaration. Generic approval was granted by 
the National Health Service National Research Ethics Service 
(approval letter dated May 13, 2016, Ref 16/NW/0274) and 
the study conducted under UKB projects No. 7155 (Principal 
Investigator J. Pell) and No. 6553 (Principal Investigator D. Smith).
Phenotyping
cIMT measurements were recorded at an imaging visit, 4 to 8 years 
after the recruitment. Starting in 2014, participants were invited to 
participate in an imaging assessment, which also included record-
ing of anthropometric measurements and completion of ques-
tionnaires covering a wide range of medical, social, and lifestyle 
information (repeated from the baseline visit). cIMT phenotyping 
began in 2015, in a pilot phase, where n=2272 individuals were at 
imaged at 18 centers (with 8 centers accounting for 98% of the 
sample) with extensive manual quality control being conducted. 
Subsequently, manual quality control was deemed unnecessary, 
and all centers began recruiting and recording automated mea-
surements (with 10 centers accounting for 93% of the sample). 
Details of the protocol are available at https://biobank.ctsu.ox.ac.
uk/crystal/label.cgi?id=101. In brief, ultrasound measurements 
of the far wall, at 2 angles on each of the left and right, of the 
distal common carotid artery with automated software recording 
images and measurements of mean and maximum intima-media 
(UKB data fields 22670-22681). Recruitment for imaging is 
ongoing, but to date (2019), N=25 769 individuals have ultra-
sound measurements of the cIMT. Three measures were calcu-
lated: The average of 4 mean measures (2 for each of the left 
and right carotid arteries) was calculated for the mean (average 
of mean cIMT values [IMTmean]); the maximum IMT (average of 
maximum cIMT values [IMTmax]), where the largest of the 4 maxi-
mum IMT measures was used; the mean of 4 maximum measures 
(2 for each of the left and right carotid arteries) was calculated 
(IMTmean-max), for comparison with previous analyses.4,6 Where 
>1 value was missing due to poor quality of the image, the partici-
pant was excluded from analyses. Values were expressed in mm 
and natural log-transformed for normality before analysis.
In the follow-up assessment, anthropometric measures, 
lifestyle variables, medication, and disease history was again 
recorded including age, weight, waist circumference, hip cir-
cumference, waist:hip ratio, body mass index (BMI), systolic 
and diastolic blood pressure (SBP and DBP respectively), 
hypertension (defined as SBP ≥140 mm Hg or DBP ≥90 mm 
Nonstandard Abbreviations and Acronyms
BMI body mass index
cIMT carotid intima-media thickness
DBP diastolic blood pressure
GWAS genome-wide association study
HDL high-density lipoprotein
IMTmax average of maximum cIMT values
IMTmean average of mean cIMT values
LD linkage disequilibrium
SBP systolic blood pressure
SNPs single nucleotide polymorphisms
UKB UK Biobank
Highlights
• This is the largest genome-wide association study 
using consistent carotid intima-media thickness 
(cIMT) phenotyping to date.
• We identified 2 novel loci for average of mean cIMT 
values, 1 novel locus for average of maximum cIMT val-
ues, and 1 for average of mean cIMT values–average 
of maximum carotid intima-media thickness values.
• In the first sex-specific analysis of average of mean 
cIMT values we identified a women-specific locus.
• Genetic correlations with previous IMT meta-
analyses, obesity, and glucometabolic traits were 
identified.
• VCAN and SVIL were highlighted as good candidate 
genes in 2 of the novel loci.
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Hg or antihypertensive medication), probable type 2 diabetes 
mellitus (T2D, coding as per Eastwood et al10), ischemic heart 
disease (ISH, defined as heart attack or angina diagnosed by a 
doctor, data field 6150), stroke (defined as stroke diagnosed by 
a doctor, data field 6150). Corrected SBP and DBP, reflecting 
probable untreated levels, were calculated as per Ehret et al.11 
These contemporary values were used in the analysis of cIMT.
Genotyping
DNA was extracted from blood samples provided by partici-
pants, using standard protocols. Details of the UKB genotyping 
and imputation procedures have been described previously.12,13 
Briefly, the full genetic data release (March 2018) was used for 
this study. Genotyping, preimputation quality control, imputation, 
and postimputation quality control were conducted centrally by 
UKB, according to standard procedures.
Statistical Analyses
Descriptive statistics and Spearman rank correlations were con-
ducted using Stata. Only individuals of self-reported white British 
ancestry were included in the genome-wide association study 
(GWAS) to maximize homogeneity. BOLT-LMM software was 
used to conduct genetic association analyses, to calculate herita-
bility estimates and estimates of λGC. IMTmean and IMTmax val-
ues were natural logarithm-transformed for normality, and genetic 
association analyses were conducted, adjusted for age, sex, and 
genotyping array (primary analysis) or age and genotyping array 
(secondary analyses). BOLT-LMM software models relatedness 
between individuals; therefore, genetic principle components 
were not included as covariates. SNPs were excluded if minor 
allele frequency <0.01, Hardy-Weinberg equilibrium P<1×10-6, 
or imputation score <0.3. Genome-wide significance was set at 
P<5×10-8, with suggestive evidence of association being set at 
P<1×10-5. After quality control, there were 22 179 participants 
with IMT and genetic data for analysis.
Genetic association results were visualized using 
FUMA software14 and LocusZoom software.15
A meta-analysis of sex-specific analyses was conducted to 
assess differences in effect sizes, using GWAMA software.16,17
For analysis of ISH and stroke, only unrelated individuals 
of self-reported white British ancestry who were not included 
in the cIMT GWAS were analyzed. Genetic association analy-
sis was conducted in PLINK software,18 using a logistic model 
and assuming additive genetic effects and adjusting for age, sex, 
population structure (genetic principal components 1–8), chip, 
T2D, BMI, and current smoking.
Linkage Disequilibrium and Genetic 
Correlations
Linkage disequilibrium (LD) between analyzed SNPs in each GWAS-
significant locus was calculated and visualized in a random subset 
of 10 000 white British individuals (or 5000 individuals where the 
locus is computationally too large with 10 000 individuals) included 
in the cIMT subset, using Haploview (default settings).19
Genetic correlations between IMTmean and IMTmax and rel-
evant cardiometabolic traits were calculated using previously pub-
lished summary statistics and LD score regression.20 IMT summary 
statistics were provided by the CHARGE (Cohorts for Heart and 
Aging Research in Genomic Epidemiology) consortium (http://
www.chargeconsortium.com/). Data on glycaemic traits were con-
tributed by MAGIC (Meta-Analysis of Glucose and Insulin-Related 
Traits Consortium) investigators and were downloaded from www.
magicinvestigators.org. T2D data were contributed by the DIAGRAM 
(Diabetes Genetics Replication and Meta-Analysis) consortium 
(http://diagram-consortium.org/downloads.html). Summary sta-
tistics for lipid traits were downloaded from the Global Lipids 
Genetics Consortium website (http://lipidgenetics.org/). Data on 
anthropometric traits were downloaded from the GIANT (Genetic 
Investigation of Anthropometric Traits) consortium website (http://
portals.broadinstitute.org/collaboration/giant/index.php/Main_
Page). Coronary artery disease data were downloaded from the 
CARDIoGRAMplusC4D (Coronary Artery Disease Genome Wide 
Replication and Meta-Analysis Plus the Coronary Artery Disease 
Genetics) consortium (http://www.cardiogramplusc4d.org/). Blood 
pressure data were provided by the International Consortium for 
Blood Pressure Genetics (https://www.ncbi.nlm.nih.gov/projects/
gap/cgibin/study.cgi?study_id=phs000585.v1.p1).
Data Mining
The GWAS catalog (https://www.ebi.ac.uk/gwas/, accessed 
20190717) was used to identify previously reported associations 
with significant loci. All SNPs with at least suggestive evidence 
of association (P<1×10-5) within significantly associated loci 
were assessed for deleterious effect using the Ensemble variant 
effect predictor.21 GWAS-significant SNPs and those predicted 
by variant effect predictor to have at least moderate impact were 
assessed for effects on genotype expression patterns of nearby 
genes using the Genotype-Tissue Expression project.22 Functions 
of highlighted genes were explored using the National Centre 
for Biotechnology Information Gene platform (https://www.ncbi.
nlm.nih.gov/gene/, accessed 20190717) and literature identified 
using National Centre for Biotechnology Information PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/, accessed 20190717).
RESULTS
Demographic characteristics of the UKB cIMT subset 
are presented in Table 1. The UKB cIMT subset consists 
of 48.3% men. Women were slightly younger (average 
62.4 years) and were healthier (average BMI, 26.1 kg/
m2 and SBP 132 mm Hg; % with hypertension, 53.8) and 
smoked less (% smokers, 3.1) compared with men (aver-
age, 63.9 years; BMI, 27.0 kg/m2; 141 mm Hg; % hyper-
tension, 69.0; smokers, 4.2). Values for both IMTmean 
and IMTmax were lower in women than in men. Mea-
surements of IMTmean and IMTmax were highly corre-
lated (Spearman Rho=0.87, P<0.0001 [full cIMT subset], 
rho=0.868 P<0.0001 [men] and Rho=0.852 P<0.0001 
[women]). IMTmean and IMTmax were significantly and 
positively associated with classical risk factors, including 
increasing age, obesity, and blood pressure (Table 2).
Primary Analysis: SNPs Associated With IMTmean 
and IMTmax
Manhattan and QQ plots of the GWAS results are presented 
in Figure 1. There was some evidence of inflation for both 
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IMTmean and IMTmax (λGC=1.15 and 1.10, respectively); 
however, this is likely due to polygenicity rather than popu-
lation structure (linkage disequilibrium score regression 
intercept [SE]=1.03 [0.03] for both phenotypes). Figure I in 
the online-only Data Supplement demonstrates the genetic 
homogeneity of the participants included in the analyses.
GWAS-significant evidence of association with IMT-
mean was observed for 176 SNPs in 8 loci (Figure 1A), 
and 76 SNPs in 3 loci demonstrated GWAS-significant 
evidence of association with IMTmax (Figure 1B). The 
lead SNP for each locus is provided in Table 3. As BOLT-
LMM includes neighboring SNPs in the model (essen-
tially conditioning on other SNPs in the region), each 
locus reported here is independent and contains only a 
single signal. Effect sizes of all lead SNPs were compa-
rable with those previously reported (β, 0.0091–0.441).6
Of the 8 loci significantly associated with IMTmean 
identified here, 4 are novel (chromosome 7, lead SNP 
rs342988; chromosome 8 [124.6 Mb], rs34557926; 
chromosome 11, rs2019090; chromosome 19 [41.3 
Mb], rs111689747; Figure 2A through 2D), and 4 have 
previously been reported (Figure 2E through 2H).
In the previously reported loci, on chromosome 5 there 
are a handful of SNPs which reach GWAS-significant 
evidence for association with IMTmean, where the lead SNP 
(rs758080886) is located 3.417 kb from the previously 
reported lead SNP rs224904.6 rs758080886 is not avail-
able in the reference panel used by LocusZoom15 and is, 
therefore, not plotted; hence, this region is represented by 
the previously reported SNP, rs224904. The LD between 
rs75808088 and rs224904 is moderate (r2=0.44); there-
fore, rs224904 is not a good proxy; however, this is the same 
for all SNPs in the locus (Figure II in the online-only Data 
Supplement). On chromosome 8, rs2912062 is 0.738 kb 
from the previously reported lead, rs2912063, and in high 
LD (r2=0.98), demonstrating that these SNPs represent the 
same signal. On chromosome 16, the lead SNP, rs561732, 
is 22.3 kb from the previously reported lead, rs844396, with 
moderate LD (r2=0.66). The chromosome 19 lead here, 
rs1065853, is 1.15 kb from the reported rs7412 but with 
almost complete LD (r2=0.99). The novel chromosome 19 
locus is ≈4 Mb from this signal, and although long-range LD 
is possible, the calculated LD between rs111689747 and 
rs1065853 or rs7412 does not support this possibility (r2=0).
There were 3 GWAS-significant loci for IMTmax. Of 
these, 2 overlap with those for IMTmean: the lead SNPs 
for IMTmean and IMTmax on chromosome 7 (rs342988 
and rs11762074, respectively) are 26.9 kb apart with LD 
of r2=0.77. For chromosome 19, the locus not only over-
laps, but the lead SNP is the same for both traits. The 
chromosome 11 for IMTmax (20.5 Mb) is distinct from 
that for IMTmean (103.6 Mb; Figure 2I).
When considering SNPs significantly associated with 
IMTmean, the direction of effects on IMTmax are consistent 
with those for IMTmean, and the magnitude is similar (Table I 
in the online-only Data Supplement). The same is true for the 
chromosome 11 IMTmax SNP, rs11025608, which shows a 
similar effect size and direction in IMTmean (β, −0.008; [SE] 
0.002; P=1.6×10-6). Therefore, further analyses focused on 
IMTmean for more robust comparisons with previous studies.
UKB IMT GWAS and the CHARGE Consortium 
IMT GWAS Meta-Analysis
The largest GWAS meta-analysis of cIMT previously 
published by the CHARGE consortium6 included 68 962 
individuals from 30 studies with a variety of recruitment 
strategies, inclusion criteria, and measurements of cIMT. 
In this study, IMTmean-max was analyzed. The range 
of average ages was 37.7 to 78.8 years, and average 
IMTmean-max was 0.50 to 1.13 mm. The single largest 
study within the meta-analysis included 8663 individuals 
(approximately evenly split between men and women).
The UKB study (N=22 179) is within the age and cIMT 
ranges reported by the CHARGE consortium, albeit on the 
younger and healthier end of the spectrum. IMTmean-max 
in UKB was highly correlated with IMTmean (Rho=0.964; 
P<0.0001) and IMTmax (Rho=0.931; P<0.0001). GWAS 
results of IMTmean-max (Figure 1C) demonstrated similar 
results to those for IMTmean, with 6 loci being identified. 
Table 1. Demographics of the UKB Cohort With cIMT  
Measurements
Men Women All
N (%) 10 708 (48.3) 11 471 (51.7) 22 179
Age, y 63.9 (7.6) 62.4 (7.3) 63.1 (7.5)
Weight, kg 83.8 (13.2) 69.2 (13.9) 76.2 (15.0)
Waist, cm 94.0 (10.4) 82.6 (11.5) 88.1 (12.4)
Hip, cm 101.2 (7.2) 101.4 (9.8) 101.3 (8.6)
WHR 0.93 (0.06) 0.81 (0.07) 0.87 (0.09)
BMI, kg/m2 27.0 (3.8) 26.1 (4.7) 26.5 (4.3)
SBP, mm Hg 141 (17) 134 (18) 137 (18)
DBP, mm Hg 80 (10) 77 (10) 79 (10)
Corrected SBP, mm Hg* 145 (19) 137 (20) 141 (10)
Corrected DBP, mm Hg* 83 (11) 79 (11) 81 (11)
IMTmean, mm 0.706 (0.135) 0.658 (0.109) 0.682 (0.125)
IMTmax, mm 0.952 (0.216) 0.875 (1.86) 0.912 (0.204)
IMTmean-max, mm 0.823 (0.159) 0.764 (0.131) 0.793 (0.148)
N hypertension 7320 (69.0) 6121 (53.8) 13 441 (61.2)
N on BPmedication 3026 (28.4) 1973 (17.3) 4999 (22.7)
N on lipid-lowering medi-
cation
3255 (34.5) 1681 (17.7) 3255 (34.5)
N probable t2d 614 (5.7) 325 (2.8) 939 (4.2)
N ISH 275 (2.6) 97 (0.9) 372 (1.7)
n current smoking 444 (4.2) 356 (3.1) 800 (3.6)
BMI indicates body mass index; BP, blood pressure; cIMT, carotid intima-media 
thickness; DBP, diastolic BP; IMT, intima-media thickness; IMTmax, average of 
maximum cIMT values; IMTmean, average of mean cIMT values; ISH, ischemic 
heart disease; SBP, systolic BP; t2d, type 2 diabetes mellitus; UKB, UK Biobank; 
and WHR, waist:hip ratio.
*Adjusted for blood pressure medication as per Ehret et al.11
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Of these, 5 had the same lead SNP as for IMTmean, and 1 
locus on chromosome 10 was novel (lead SNP rs2150562; 
Table 3; Figure 2J). In the analysis of IMTmean, this locus 
reached suggestive significance (β=0.008, [SE]=0.002, 
P=1.5×10-6). All loci reaching GWAS-significance 
(P<5×10-8) for IMTmean or IMTmax demonstrated at least 
suggestive (P<1×10-6) significance with IMTmean-max 
(Table I in the online-only Data Supplement).
The CHARGE meta-analysis reported 11 robustly associ-
ated loci,6 of which 9 lead SNPs were available in UKB (Table 
II in the online-only Data Supplement). Seven of these dem-
onstrated significant (P<0.05) associations with IMTmean 
and IMTmean-max, with consistent effect directions, when 
compared with the previous report6 (Table II in the online-only 
Data Supplement). One SNP demonstrated a nonsignificant 
association, and one demonstrated a significant association 
but inconsistent direction (Table II in the online-only Data 
Supplement), for both IMTmean and IMTmean-max.
Of the lead SNPs identified in UKB, 11 were avail-
able in the CHARGE meta-analysis (Table III in the 
online-only Data Supplement). Of these, 10 were signifi-
cant (P<0.05) with consistent effect directions to those 
reported in UKB. One lead SNP was not significant. 
Effects sizes were generally 2- to 3-fold larger in UKB 
than in the CHARGE meta-analysis. The effect sizes of 
the cIMT-associated lead SNPs are summarized in Fig-
ure III in the online-only Data Supplement.
Secondary Analyses: Sex-Specific Genetic 
Effects on IMT
Sex-specific analyses suggest that the genetic variants 
associated with IMTmean in men and women are distinctly 
different (Figure 3): In men-only analyses (Figure 3A), 3 
GWAS-significant loci were identified on chromosome 7 
(rs35099106), chromosome 8 (6.4 Mb, rs2912063), and 
chromosome 19 (rs1065853), all of which overlap with 
those identified in the primary (sex combined) analysis 
(Table 3 and Figure 4). The chromosome 7 lead SNP is 
in strong LD with that for IMTmax (rs11762074; r2=0.97) 
but only moderate LD with the sex-combined IMTmean 
lead SNP (rs342988; r2=0.64). The lead SNPs on chro-
mosome 8 and 19 are consistent either with the primary 
analysis or with previously reported lead SNPs.
In an analysis of women (Figure 3B), only a locus on chro-
mosome 5 was GWAS-significant (Table 3 and Figure 4). The 
lead SNP for this locus, rs309563, is ≈1.2 Mb from, and dem-
onstrated no LD with, the lead sex-combined SNP for IMT-
mean (rs758080886, r2=0) or the previously reported lead 
SNP for this locus (rs224904, r2=0, Figure II in the online-
only Data Supplement), suggesting that it is a separate locus.
Effect directions for SNPs with suggestive evidence of 
association were consistent between men and women. All 
3 loci identified in the men-only analysis have concordant 
effect directions (same direction of effect, but different 
sizes between the sexes23), where effect sizes were halved 
in women but at least nominal significance being observed 
for most SNPs and suggestive significance noted for the 
chromosome 19/APOE locus (Table IV in the online-only 
Data Supplement). In contrast, the chromosome 5 locus 
identified in the women-only analysis is a single-sex effect 
locus,23 that is to say it demonstrates nonsignificant associ-
ations in men (Table IV in the online-only Data Supplement). 
In all 4 loci, SNPs demonstrated significant heterogene-
ity between men and women (with I2>0.75 and P<0.047; 
Table IV in the online-only Data Supplement).
Impact of cIMT-Associated Variants on ISH and 
Stroke in UKB
Demographic characteristics of the individuals 
included in the analyses of ISH and Stroke are 
Table 2. Correlations Between cIMT and Classical Cardiovascular Disease Risk Factors
Men Women All
IMTmean IMTmax IMTmean IMTmax IMTmean IMTmax
Rho P Value Rho P Value rho P Value Rho P Value Rho P Value Rho P Value
Age, y 0.385 <0.0001* 0.320 <0.0001* 0.465 <0.0001* 0.397 <0.0001* 0.433 <0.0001* 0.369 <0.0001*
Weight, kg 0.062 <0.0001* 0.117 <0.0001* 0.057 <0.0001* 0.121 <0.0001* 0.147 <0.0001* 0.204 <0.0001*
Waist, cm 0.109 <0.0001* 0.169 <0.0001* 0.105 <0.0001* 0.176 <0.0001* 0.179 <0.0001* 0.243 <0.0001*
Hip, cm 0.073 <0.0001* 0.122 <0.0001* 0.075 <0.0001* 0.134 <0.0001* 0.078 <0.0001* 0.130 <0.0001*
WHR 0.100 <0.0001* 0.150 <0.0001* 0.087 <0.0001* 0.140 <0.0001* 0.190 <0.0001* 0.236 <0.0001*
BMI, kg/m2 0.089 <0.0001* 0.152 <0.0001* 0.073 <0.0001* 0.148 <0.0001* 0.105 <0.0001* 0.174 <0.0001*
SBP, mm Hg −0.030 0.0054* 0.001 0.9306 0.025 0.0145* 0.051 <0.0001* 0.083 <0.0001* 0.117 <0.0001*
DBP, mm Hg 0.237 <0.0001* 0.216 <0.0001* 0.324 <0.0001* 0.297 <0.0001* 0.320 <0.0001* 0.308 <0.0001*
Corrected SBP, mm Hg† 0.021 0.0534 0.055 <0.0001* 0.071 <0.0001* 0.099 <0.0001* 0.030 <0.0001* 0.061 <0.0001*
Corrected DBP, mm Hg† 0.250 <0.0001* 0.239 <0.0001* 0.333 <0.0001* 0.313 <0.0001* 0.306 <0.0001* 0.286 <0.0001*
BMI indicates body mass index; cIMT, carotid intima-media thickness; DBP, diastolic blood pressure; IMT, intima-media thickness; IMTmax, average of maximum cIMT 
values; IMTmean, average of mean cIMT values; SBP, systolic blood pressure; and WHR, waist:hip ratio.
*Indicates nominally significant values (P>0.05).
†Adjusted for blood pressure medication as per Ehret et al.11
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presented in Tables IX and X in the online-only 
Data Supplement, respectively. Unsurprisingly, ISH 
and stroke cases had higher age, BMI, and rates 
of hypertension and blood pressure and lipid-
lowering medication. Two IMT-associated SNPs 
(rs758080886 and rs1065853) were nominally 
Figure 1. QQ and Manhattan plots of results of the genome-wide association study of (A) average of mean carotid intima-
media thickness (cIMT) values (IMTmean), (B) average of maximum cIMT values (IMTmax), and (C) IMTmean-max.
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(P<0.05) associated with stroke (Table XI in the 
online-only Data Supplement) but did not withstand 
multiple testing correction (13 SNPs, P<0.0038). 
Three IMT-associated SNPs were associated with 
ISH, 2 of which survived multiple testing correction 
(Table XI in the online-only Data Supplement). The 
effects of rs2019090 and rs1065853 were in the 
expected direction, with the allele associated with 
increased IMTmean measures being associated with 
increased risk of ISH.
Genetic Correlations With Cardiovascular 
Phenotypes and Risk Factors
UKB IMTmean, IMTmax, and IMTmean-max GWAS 
demonstrated significant genetic correlations with the 
CHARGE GWAS IMTmean meta-analyses (regression 
coefficient [rg]=0.74–0.82, Table 4).4,6 As the individu-
als included in the IMTmean, IMTmax, and IMTmean-max 
analyses overlap completely was not possible to compare 
these analyses. Significant positive genetic correlations 
Table 3. Lead SNPs in Loci Associated With cIMT
Analysis SNP CHR Locus* Genes Under the Locus A1 A0
A1 
Freq β SE χ2 P Value
GWAS 
SNPs in 
Locus
IMTmean 
sex com-
bined
rs758080886 5  ATG10, RPS23, ATP6AP1L CA C 0.15 0.013 0.002 30.6 3.10×10−8 1
rs342988†,§ 7 35423859-
35528567
LOC401324 C T 0.28 0.011 0.002 44.2 3.00×10−11 78
rs2912062║ 8 6470650-
6494850
MCPH1, MIR8055 C G 0.71 0.012 0.002 56.2 6.70×10−14 56
rs34557926† 8 124579985-
124608614
FBXO23, KLHL38, ANAXA13 C T 0.64 -0.011 0.002 48.8 2.90×10−12 4
rs2019090† 11 103660567-
103673294
MIR4693 A T 0.29 0.009 0.002 33.2 8.20×10−9 5
rs561732 16 88966667-
88989862
CBFA2T3, LOC100129697, 
TRAPPC2L
T C 0.65 0.009 0.002 34.8 3.60×10−9 22
rs111689747† 19 41188985-
41371458
CYP2A6, CYP2A7, CYP-
2G1PCYP2B7P, CYP2B6, 
SNRPA, MIA, EGLN2, RAB4B, 
MIA-RAB4B, RAB4B-EGLN2, 
C19ORF54, ITPKC, ADCK4, 
NUMBL, LTBP4, SHKBP1, 
SPTBN4
G A 0.99 -0.044 0.007 41.5 1.20×10−10 3
rs1065853‡ 19 45412079-
45426792
BCAM, PVRL2, TOMM40, 
APOE, APOC1, APOC1P1, 
APOC4-APOA2, APOC2, 
CLPTM1, APOC4, RELB
G T 0.92 0.021 0.003 60.8 6.20×10−15 7
IMTmax sex 
combined
rs11762074§ 7 35428513-
35505204
LOC401324 T C 0.77 -0.014 0.002 39 4.30×10−10 63
rs11025608† 11  PRMT3, SLC6A5 G T 0.44 -0.010 0.002 30.6 3.20×10−8 1
rs1065853‡ 19 45389596-
45426792
BCAM, PVRL2, TOMM40, 
APOE, APOC1, APOC1P1, 
APOC4-APOA2, APOC2, 
CLPTM1, APOC4, RELB
G T 0.92 0.026 0.003 56.1 6.90×10−14 11
IMTmean 
men
rs35099106 § 7 35428513-
35505204
LOC401324 C CT 0.24 0.016 0.003 34.1 5.20×10−9 38
rs2912063∥ 8 6470650-
6490544
MCPH1, MIR8055 A G 0.71 0.017 0.003 44.5 2.60×10−11 24
rs1065853‡ 19 45412079-
45413233
BCAM, PVRL2, TOMM40, 
APOE, APOC1, APOC1P1, 
APOC4-APOA2, APOC2, 
CLPTM1, APOC4, RELB
G T 0.92 0.027 0.004 39.1 4.00×10−10 2
IMTmean 
women
rs309563† 5 82870033-
82933913
VCAN, HAPLN1 A T 0.66 -0.01 0.002 37.6 8.90×10−10 37
CHR indicates chromosome; cIMT, carotid intima-media thickness; GWAS, genome-wide association study; IMT, intima-media thickness; IMTmax, average of maximum 
cIMT values; IMTmean, average of mean cIMT values; LD, linkage disequilibrium; SE, standard error of effect; and SNP, single nucleotide polymorphism.
*Region bordered by GWAS-significant SNPs.
†Novel locus.
‡Consistent lead SNP convincingly demonstrates that the same locus is being identified.
§LD between rs342988, rs11762074, and rs35099106 suggests that these SNPs represent 1 signal.
∥LD between rs2912062 and rs2912063 indicate that these SNPs are proxies.
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Figure 2. Regional plots for novel average of mean carotid intima-media thickness (cIMT) values (IMTmean)–associated loci 
on (A) chromosome (Chr) 7 (rs342988), (B) Chr8 (rs34557926), (C) Chr11 (rs2019090), (D) Chr19 (rs111689747) and known 
IMTmean-associated loci on (E) Chr5 (rs224904, instead of lead SNP rs758080886), (F), Chr8 (rs2912062), (G) Chr16 (rs561732), 
(H) Chr19 (rs1065853) as well as (I) the novel locus for average of maximum cIMT values on Chr11 (rs11025608). (Continued )
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were observed between IMTmean and total obesity (BMI), 
T2D, fasting glucose, and insulin (Table 4). For IMTmax, 
positive correlations with total and central obesity (BMI and 
waist:hip ratio adjusted for BMI respectively), T2D, fasting 
glucose, and rheumatoid arthritis were observed (Table 4). 
It was surprising to note that a significant positive associa-
tion with HDL (high-density lipoprotein) and a significant 
negative association with fasting insulin was observed. It 
is worth noting that the fasting insulin adjusted for BMI 
demonstrated the expected direction or correlation, sug-
gesting that obesity influences the relationship between 
IMTmax and fasting insulin levels. The significance of the 
positive correlation between IMTmax and HDL is unclear. 
Genetic correlations for IMTmean-max were similar to 
those for IMTmean and IMTmax (Table 4).
In men, similar to the sex-combined results, IMTmean 
was positively genetically correlated with the CHARGE 
IMTmean meta-analyses, total obesity, fasting glucose, and 
fasting insulin. In women, only the genetic correlations with 
the CHARGE meta-analyses survive false discovery rate 
correction (Table V in the online-only Data Supplement).
Data Mining
The GWAS catalog was explored (using lead SNPs and 
locus positions, as per Table 3) to identify previous associa-
tions with the cIMT-associated loci (Table VI in the online-only 
Data Supplement). Chromosome 7 and chromosome 8 (6.4 
Mb) have previously been associated with DBP,24,25 whereas 
chromosome 11, chromosome 13, and both chromosome 
19 loci have previously been associated with coronary artery 
Figure 2 Continued. The lead single nucleotide polymorphism (SNP) is indicated by a purple diamond. Linkage disequilibrium (LD; r2) 
between other SNPs and the lead SNP is indicated by color. Gray indicates LD is not known.
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disease26–28 or pulse pressure29 or cIMT.6 The novel chromo-
some 10 locus has previously been associated with height.30 
Atherosclerosis is considered a condition requiring both 
fatty deposits and inflammation in the vascular wall. There-
fore it was interesting to note the reported associations of 
chromosome 8 (6.4 Mb) and chromosome 11 with immune 
response31 or immune components32 as well as the chro-
mosome 19 (45 Mb) locus with lipid (and other biomarker) 
levels33–50 and chromosome 7 with fatty liver disease.51
The chromosome 19 locus includes the apolipoprotein 
gene cluster (including APOE), which has been the focus of 
much research into lipid levels, cardiovascular disease, and 
Figure 3. QQ and Manhattan plots of results of the genome-wide association study of intima-media thickness mean in (A) men 
only and (B) women only.
D
ow
nloaded from
 http://ahajournals.org by on April 28, 2020
Strawbridge et al GWAS of IMT in UK Biobank
456  February 2020 Arterioscler Thromb Vasc Biol. 2020;40:446–461. DOI: 10.1161/ATVBAHA.119.313226
CL
IN
IC
AL
 A
ND
 P
OP
UL
AT
IO
N 
ST
UD
IE
S 
- A
L
Alzheimer disease. In contrast, previous associations at the 
chromosome 5, chromosome 8 (124 Mb) and chromosome 
16 loci have no obvious relevance to cIMT. For the vast major-
ity of previous associations with relevant traits (Table VI in the 
online-only Data Supplement), the effects on cIMT were in 
the expected direction: the alleles associated with increased 
DBP, SBP, pulse pressure, total cholesterol, low-density lipo-
protein, APOE and lipoprotein A levels, and lipoprotein phos-
pholipase A2 activity were associated with increased cIMT, 
as were the alleles associated with decreased HDL levels. 
The only unexpected finding was that the rs7412 allele asso-
ciated with decreasing triglyceride levels47 was associated 
with increased cIMT; however, the authors suggest that the 
skewed distribution of lipids in those homozygous for this 
allele might cause inflation of test statistics47 and that this 
should be considered when interpreting results.
Of SNPs within significantly associated loci showing at 
least suggestive evidence of association with IMTmean, 
13 SNPs were predicted21 to have functional or coding 
effects (Table VII in the online-only Data Supplement). 
Figure 4. Regional plots for sex-specific average of mean carotid intima-media thickness value–associated loci.  
Men-only loci on (A) chromosome (Chr) 7 (rs35099106), (B) Chr8 (rs2912063), (C) Chr19 (rs1065853) and the women-only locus on (D) 
Chr5 (rs309563). The lead single nucleotide polymorphism (SNP) is indicated by a purple diamond. Linkage disequilibrium (LD; r2) between 
other SNPs and the lead SNP is indicated by color. Gray indicates LD is not known.
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Lead SNPs and those predicted by variant effect predic-
tor to have functional or coding effects were assessed for 
evidence of genotype-specific effects on gene expression 
levels (expression quantitative trait loci) in the Genotype-
Tissue Expression project dataset (Table VIII in the online-
only Data Supplement). Only rs2019090 on chromosome 
11 demonstrated expression quantitative trait loci in a 
tissue of obvious relevance, namely the aorta, where the 
cIMT-increasing allele was associated with increased 
RP11-563P16.1 levels. Lack of knowledge about this 
gene's role precludes interpretation of this finding.
Candidate Genes
Of the genes highlighted by expression quantitative trait loci 
analysis (though in a tissue of unclear relevance), APOE 
(chromosome 19) has been widely studied in cardiovas-
cular (and other, notably Alzheimer) diseases,52 whereas 
the function of MCPH1-AS1(CTD-2541M15.3; chromo-
some 8) is thought to be as a regulator of MCPH1, a DNA 
damage response gene with no obvious role in vessel wall 
biology. Similarly, CBFA2T3 (chromosome 16) has docu-
mented roles in cancer biology as a transcriptional repres-
sor, but again, there is no obvious role in vascular biology.
VCAN (chromosome 5, women-only locus) is potentially 
an interesting candidate gene. Its encoded product, ver-
sican, is a chondroitin sulfate proteoglycan present in the 
adventitia and intima of normal blood vessels (reviewed in 
Wight and Merrilees53). Versican protein levels have been 
shown to increase dramatically during progression of vas-
cular diseases including atherosclerosis.53 Versican exists 
Table 4. Genetic Correlations Between IMTmean, IMTmax, and Cardiometabolic Traits and Risk Factors
IMTmean IMTmax IMTmean-max
rg SE P Value FDR-p rg SE P Value FDR-p rg SE P Value FDR-p
CHARGE IMT-
mean 2018
0.82* 0.07* 6.39×10−29* 1.53×10−27* 0.79* 0.09* 1.16×10−17* 2.79×10−16* 0.78* 0.07* 1.11×10−28* 2.67×10−27*
CHARGE IMT-
mean 2011
0.77* 0.08* 2.03×10−22* 2.44×10−21* 0.74* 0.10* 1.71×10−14* 2.05×10−13* 0.74* 0.08* 4.16×10−21* 5.00×10−20**
BMI 0.13* 0.03* 1.19×10−4* 9.50×10−4* 0.22* 0.04* 7.72×10−7* 6.17×10−6* 0.18* 0.04* 3.85×10−7* 3.08×10−6
Fasting insulin 0.30* 0.10* 2.25×10−3* 1.08×10−2* −0.17* 0.05 3.99×10−4* 1.91×10−3* 0.35* 0.10* 4.82×10−4* 2.89×10−3*
Type 2 diabetes 
mellitus
0.21* 0.08* 4.99×10−3* 2.00×10−2* 0.28* 0.09 1.15×10−3* 4.62×10−3* 0.25* 0.07* 5.39×10−4* 2.59×10−3*
Fasting glucose 0.26* 0.07* 1.91×10−4* 1.15×10−3* 0.50* 0.14 2.20×10−4* 1.32×10−3* 0.23* 0.07* 6.31×10−4* 2.52×10−3*
HDL −0.09 0.04 2.03×10−2 6.94×10−2 0.17* 0.06 4.76×10−3* 1.63×10−2* −0.13* 0.04* 6.88×10−4* 2.36×10−3*
WHR adjBMI 0.10 0.05 4.10×10−2 1.23×10−1 0.24* 0.09 6.40×10−3* 1.92×10−2* 0.13* 0.05* 4.29×10−3* 1.29×10−2*
Rheumatoid 
arthritis
0.11 0.06 8.03×10−2 2.14×10−1 0.31* 0.12* 1.16×10−2* 3.08×10−2* 0.12 0.06 4.13×10−2 1.10×10−1
Fasting insulin 
adjBMI
0.10 0.10 3.17×10−1 6.34×10−1 0.10 0.08 1.82×10−1 3.64×10−1 0.16 0.10 9.18×10−2 2.20×10−1
DBP 0.02 0.02 2.39×10−1 5.73×10−1 0.10 0.05 4.93×10−2 1.18×10−1 0.03 0.02 1.08×10−1 2.35×10−1
Smoking onset −0.15 0.15 3.29×10−1 5.63×10−1 −0.09 0.08 3.04×10−1 5.21×10−1 −0.24 0.15 1.13×10−1 2.26×10−1
Triglycerides 0.03 0.04 4.04×10−1 6.06×10−1 −0.15 0.17 3.72×10−1 5.58×10−1 0.06 0.04 1.19×10−1 2.19×10−1
Ever Smoker 0.06 0.06 3.16×10−1 6.89×10−1 0.18 0.13 1.80×10−1 3.93×10−1 0.09 0.06 1.46×10−1 2.50×10−1
Cholesterol −0.06 0.06 3.22×10−1 5.94×10−1 −0.07 0.06 2.41×10−1 4.46×10−1 −0.09 0.07 1.73×10−1 2.78×10−1
SBP 0.02 0.02 4.32×10−1 6.10×10−1 0.06 0.08 4.18×10−1 5.89×10−1 0.03 0.02 1.83×10−1 2.75×10−1
Ciggarettes per 
day
0.05 0.11 6.42×10−1 8.11×10−1 0.10 0.17 5.51×10−1 6.96×10−1 0.11 0.11 3.10×10−1 4.37×10−1
Ulcerative collitis −0.05 0.08 5.34×10−1 7.12×10−1 0.02 0.02 4.79×10−1 6.39×10−1 −0.07 0.07 3.29×10−1 4.39×10−1
Fasting proinsulin 0.13 0.14 3.54×10−1 5.66×10−1 −0.08 0.08 3.24×10−1 5.18×10−1 0.12 0.14 3.89×10−1 4.92×10−1
Cardiovascular 
disease
−0.07 0.21 7.59×10−1 8.28×10−1 −0.03 0.07 6.05×10−1 6.60×10−1 −0.18 0.23 4.26×10−1 5.11×10−1
LDL −0.01 0.05 7.80×10−1 8.14×10−1 0.01 0.02 6.43×10−1 6.71×10−1 −0.04 0.05 4.67×10−1 5.33×10−1
2 h glucose −0.02 0.12 8.62×10−1 8.62×10−1 −0.01 0.06 8.92×10−1 8.92×10−1 0.06 0.12 5.92×10−1 6.46×10−1
Irritatable bowel 
disorder
−0.02 0.05 7.18×10−1 8.20×10−1 0.08 0.15 5.71×10−1 6.53×10−1 −0.02 0.05 6.69×10−1 6.98×10−1
Crohn disease 0.02 0.06 7.16×10−1 8.60×10−1 −0.16 0.29 5.66×10−1 6.79×10−1 0.01 0.06 8.82×10−1 8.82×10−1
adjBMI indicates adjusted for BMI; BMI, body mass index; CHARGE, Cohorts of Heart and Aging Research in Genomic Epidemiology consortium; cIMT, carotid 
intima-media thickness; DBP, diastolic blood pressure; FDR-P, false discovery rate-corrected P value; HDL, high-density lipoprotein; IMT, intima-media thickness; IMTmax, 
average of maximum cIMT values; IMTmean, average of mean cIMT values; LDL, low-density lipoprotein; rg, regression coefficient; SBP, systolic blood pressure; SE, 
standard error of effect; and WHR, waist:hip ratio.
*Indicates nominally significant values (P>0.05).
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as a variety of protein isoforms of different sizes, due to 
alternative splicing, a variety of post-translational modifi-
cations, and proteolytic cleavage.53 The diverse effects of 
versican in vascular pathology are likely determined by the 
balance of different sized isoforms and partners in com-
plexes53: larger molecules are better able to bind and thus 
retain low-density lipoprotein L in the vessel wall; loss of 
the largest versican isoform has been observed in aor-
tic aneurysms; various cytokines promote different sized 
versican entities or versican degradation; smaller versican 
isoforms could act directly as mitogens for arterial smooth 
muscle cells; and the smallest isoform of versican influ-
ences elastic fiber formation and, therefore, vessel func-
tion. Therefore, it is interesting to note that the lead SNP 
for the women-only locus is an expression quantitative 
trait loci for a versican antisense molecule, VSCAN1-AS1, 
in testes, suggesting yet another mechanism regulating 
versican expression, although the role of versican in the 
testes is unknown. Full understanding of versican biology 
is required before the impact of this SNP is predictable.
SVIL in the novel chromosome 10 locus encodes 
supervilin, which is a cytoskeleton-regulating protein 
that influences platelet reactivity.54 Supervillin levels have 
been associated with platelet function in response to 
shear stress (in humans and mice), with increased lev-
els of supervillin being associated with reduced thrombus 
formation54; therefore, it was interesting to note that the 
allele associated with increased IMTmean-max measures 
(rs2150562-A) was associated with reduced SVIL levels 
in the aorta (Table VIII in the online-only Data Supplement) 
but not with heart disease or stroke outcomes (Table IX in 
the online-only Data Supplement). However, the lead SNP 
for IMTmean-max, rs2150562 is ≈350 kb upstream of a 
variant, which has been associated with platelet thrombus 
formation, rs707067854 and LD between rs2150562 and 
rs7070678 was 0 (R2). This suggests that the signal for 
IMTmean-max is distinct from that associated with plate-
let function. There are multiple isoforms of supervillin, with 
incompletely characterized functions.55 However, there is 
evidence that at least 1 isoform influences cell migra-
tion and proliferation,55 which are of relevance to athero-
sclerosis pathology. How the genetic variants influence 
Supervillin isoforms is as yet unclear.
DISCUSSION
Here, we present results from a GWAS of the largest 
single study of cIMT to date, and the first sex-specific 
analysis of cIMT. We identified 11 loci (5 of which were 
novel) associated with cIMT (mean, max or mean-max) 
and 1 locus specific for IMTmean in women. We also 
found genetic correlations with obesity, glucometabolic, 
and lipid traits, which suggest differences between sexes.
Many studies have reported the utility of cIMT measure-
ments as predictors of cardiovascular disease (reviewed 
by Katakami et al56), although whether predictive power is 
independent of traditional risk factors is still unclear. A large 
part of the discrepancies in the literature is likely due to the 
different protocols used (which part of the carotid artery is 
measured, whether plaque is included or not, whether mean 
or plaque [defined by a specific maximum value] is used) in 
the analyses. It is worth noting that IMTmean-max is most 
often analyzed, with IMTmax rarely being analyzed a quan-
titative trait, rather this measure is normally used to define 
the presence of plaque (as described6). Although plaque is 
clearly a relevant phenotype, we used the better-powered 
continuous IMTmax values to explore the possibility of dif-
ferent genetic regulation and potentially different mecha-
nisms influencing mean and maximum cIMT measures.
Indeed it has been reported that IMTmean and IMT-
max differ in their predictive value.56 Therefore, the partial 
overlap in loci associated with IMTmean and IMTmax is of 
interest. For the most part, SNPs influencing one pheno-
type also influence the other, but the relative importance of 
each locus (or mechanism) differs. This hints at differences 
in biology between the 2 measures, which is perhaps not 
surprising: overall increases in vascular wall thickness could 
indicate general vascular dysfunction, which is a component 
of high blood pressure for example. Local increases in vas-
cular wall thickness are likely indicative of plaque formation, 
which precede vessel occlusion and ischemic events.
Our results demonstrate that only a minority of SNPs 
associated with cIMT measures have significant effects 
on cardiovascular end points, namely ISH or stroke, 
which is consistent with previous reports.6 It was reassur-
ing to note that the 2 SNPs with effects on ISH had the 
expected effects, with increased cIMT being associated 
with increased risk of ISH and that one of these SNPs 
was previously associated with myocardial infarction.27
Sex-specific differences in cardiovascular disease are 
well established; therefore, the distinctly different IMT-
mean GWAS results for men compared with women were 
intriguing. The existence of a women-only locus, whereas 
the men-only analysis largely resembled the sex-combined 
analysis, is unexpected. It suggests that the sex-combined 
results could be driven by the men. This is unlikely given the 
fairly balanced sex distribution of the sample (48% men 
versus 52% women); however, the larger variability in mea-
sures in men compared with women could cause this effect. 
It has been observed that sex differences in IMT measures 
can be attributed to sex differences in risk factors, such as 
BMI and blood pressure.57 Despite UKB being ≈20 years 
older than the subjects in that study, similar sex differences 
in risk factors are observed here. It is also worth noting that 
menopause status is associated both with cIMT measures 
and cardiovascular risk factors.58,59 Menopause status was 
not considered in the study, as direction of effect is unclear. 
However, this factor would be worth considering for future 
studies of sex differences.
Another noteworthy finding is the stronger effect of 
APOE rs7412 in men compared with women (β=0.027 
versus 0.016, respectively). To our knowledge, this is the 
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first demonstration of a sex effect of APOE variation in a 
cardiovascular disease phenotype, which is of value when 
considering the relatively nascent concept of an aging, 
sex, and APOE triad.60 Sex-specific differences in APOE-e 
genotypes associations with Alzheimer disease have been 
noted (summarized by Fisher et al61), with female carriers 
of APOE-e3/e4 demonstrating increased risk of Alzheimer 
disease and faster decline than their male counterparts. 
Indeed, this finding (a variant that increases risk of ath-
erosclerosis for men and Alzheimer disease for women) 
supports the hypothesis that women have higher rates for 
Alzheimer disease than men, at least partly because men 
with cardiovascular disease die earlier than women; there-
fore, in the at-risk age-range for Alzheimer disease, men 
have lower cardiovascular risk than women.61
In line with known epidemiology and previous genetic 
findings,62 the genetic correlations between IMTmean, 
IMTmax, or IMTmean-max and obesity and glucometabolic 
traits are unsurprising. It is worth noting that genetic corre-
lations between coronary artery disease (ie, cardiovascular 
end points) and fasting insulin or glucose are quite strong 
but not reported due to their unimpressive P values (rg 
0.23 [se 0.11], P=0.041 and 0.14 [0.09] P=0.095 respec-
tively).63 Rheumatoid arthritis demonstrates weak and 
nonsignificant associations with coronary artery disease 
(−0.06 [0.08], P=0.438), but a moderate and nominally 
significant association with IMTmax. Taken together these 
findings suggest different mechanisms are important dur-
ing subclinical atherosclerosis compared with clinically 
evident cardiovascular disease. The lack of genetic cor-
relations between IMTmean and lipid traits is unexpected 
but may reflect the relative health, adherence to statin 
therapy, or healthy diet of the general population sample 
of UKB. Similarly, we cannot exclude the possibility that 
the relative health or use of statin therapy contributes to 
the unexpected positive correlation between IMTmax and 
HDL. As this is the first time IMTmax has been analyzed 
using a GWAS and genetic correlations, it is not possible 
to validate or further explore this finding.
In comparison with the CHARGE consortium cIMT 
meta-analysis, this study was smaller (N=22 000 versus 
N=68 000) but used a phenotype that was recorded in a 
consistent manner in all individuals, reducing heterogene-
ity in measurements. This is likely the reason for identifying 
loci not reported by CHARGE as well as the larger effect 
sizes reported here and is in line with previous observations 
(eg, the C4D26 and CARDIoGRAM findings64). In light of 
the recently identified issues with some genotyping in UKB 
(exemplified by Wei et al65), quality control measures for 
lead SNPs are reported in Table XII in the online-only Data 
Supplement. For all but one lead SNP, these measures indi-
cate no issues. Only rs11025608 should be viewed with 
caution until replication of this signal has been conducted.
It should be noted that the location of measurements 
relative to the bifurcation is not specified and that there is 
some evidence of inflation of the GWAS statistics, for which 
there are a number of possible explanations. Polygenicity is 
an obvious explanation and highly plausible, as it is observed 
most complex traits. Although the pilot phase cIMT data 
(n=2500) underwent manual quality control procedures, the 
full IMT dataset (N=22 000) did not. Comparisons between 
the quality controlled and non-quality controlled data in the 
pilot study show very high correlation (IMTmean rho=1.0, 
IMTmax rho=0.98); however, the possibility of noise in mea-
surements cannot be excluded. Despite this limitation, the 
consistent effect sizes and directions of most previous IMT 
loci suggest that this study is valid.
In conclusion, we have conducted a GWAS of cIMT 
(mean and maximum measures) in the largest single study 
sample to date, in which we identified 4 novel loci and vali-
dated 7 of 11 previously reported loci. We also report the 
first sex-specific analysis of IMT, in which we identified a 
novel women-only locus. Genetic correlations with obesity 
and glucometabolic traits were observed, and VCAN was 
highlighted as a plausible candidate gene in the women-only 
locus. Overall, our findings represent an important stimulus 
for the further elucidation of mechanisms of vascular pathol-
ogy, particularly differences between men and women, and 
could contribute to stratified medicine approaches.
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